Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Phase 1, open-label, non-randomized, dose-escalation study to evaluate the safety,
tolerability, pharmacokinetics (PK), and preliminary efficacy of HBI-8000 administered
orally.